$AEON SEC Filings

Filed On	Filing
26 Oct 2026	Proxy statement: special meeting on December 15, 2026
23 Oct 2026	8-K: Regulation FD Disclosure Disrupting a $3.5B neurotoxin market dominated by a single brand for >30 years CORPORATE PRESENTATION / OCTOBER 2026 NYSEAMERICAN: AEON © 2 0 2 6 A E O N B I O P H A R M A
13 Oct 2026	PRE 14A
30 Sep 2026	8-K: Regulation FD Disclosure; Other Events FDA indicated previously completed ABP-450 head-to-head studies versus BOTOX® may be submitted as supportive evidence; AEON expects to advance the required scientific bridging work
21 Aug 2026	SCHEDULE 13G
21 Aug 2026	Form 4: Lynch Timothy P, 10% owner Bought 1,150,000 shares ($243K)
21 Aug 2026	Form 3: Lynch Timothy P, 10% owner Holds 5,350,000 shares of Class A Common Stock
12 Aug 2026	10-Q
12 Aug 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
03 Aug 2026	8-K: Regulation FD Disclosure; Other Events
23 Jul 2026	8-K: Other Events
21 Jul 2026	SCHEDULE 13G
15 Jul 2026	8-K: Entry into a Material Definitive Agreement; Other Events
15 Jul 2026	424B4
13 Jul 2026	EFFECT
13 Jul 2026	S-1MEF
09 Jul 2026	S-1/A
08 Jul 2026	S-1
22 Jun 2026	Form 4: Thunen Shelley B, Director Received 222,684 shares as a grant or award
22 Jun 2026	Form 4: Palmisano Robert J, Director Received 222,684 shares as a grant or award

Comments